A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

Summary

This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.

Timeline

Start

2025-06-09

Primary completion

2027-05

Completion

2027-05

Drugs

Indications